Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection

1Angela Maria e Antonio Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

2Hepato-Oncology Group, Department of Gastroenterology and Surgery, IRCCS National Cancer Institute, Milan, Italy

Hepatitis Monthly:Vol. 12, issue 6; 411-414

Published online:Jun 30, 2012

Article type:Case Report

Received:May 07, 2012

Accepted:May 31, 2012

How to Cite:Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M, Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection.Hepat Mon.2012;12(6):411-414.https://doi.org/10.5812/hepatmon.6135.

Abstract

Background: Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) remains a serious problem in the clinical management of post-OLT patients. Recently, two case reports have described successful prevention of HCV liver graft reinfection with intravenous silibinin (SIL) monotherapy in two carriers of genotype 3a and 1a/4 HCV. Based on these findings, we decided to offer such a therapy to a 65 year old woman on the OLT list.
Case Presentation: A 65 year old patient with HCV 2a cirrhosis, a previous relapse to PegIFN and Rbv therapy, was listed for OLT due to hepatocellular carcinoma. She started SIL monotherapy 24 hours before OLT. After an initial HCV-RNA decline following surgery, a progressive HCV RNA increase was observed. For this reason, SIL was stopped after 15 days of monotherapy.
Conclusions: SIL has multiple anti-HCV mechanisms of action, most of them have been characterized in vitro only. Our case report shows that the antiviral effect of SIL might be HCV genotype dependent, as recently suggested by a study, showing no effect of SIL on the HCV-2a subgenomic replicon model. Our case reinforces the need for controlled studies to assess the efficacy of silibinin therapy in HCV infected patients before it can be broadly used in all clinical settings.

Implication for health policy/practice/research/medical education:
Silibinin monotherapy is a promising therapeutic option for HCV patients. Our article demonstrates that Silibinin has no effect on genotype 2 HCV, reinforcing the need for controlled studies on this drug before it can be routinely used in clinical practice.
Please cite this paper as:
Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. Hepat Mon. 2012;12(6): 411-4. DOI: 10.5812/hepatmon.6135

Keywords

Hepacivirus

Silybin

Liver Transplantation

Fulltext

Full text is available in PDF

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Alessio Aghemo:[PubMed][Scholar]
Sherrie Bhoori:[PubMed][Scholar]
Stella De Nicola:[PubMed][Scholar]
Vincenzo Mazzaferro:[PubMed][Scholar]
Massimo Colombo:[PubMed][Scholar]